Monopar Therapeutics (MNPR)
Develops ALXN1840 for Wilson disease and MNPR-101 radiopharmaceuticals for oncology.
Something off on this page? Send us feedback.
Builds a clinical-stage pipeline around late-stage ALXN1840 for Wilson disease and MNPR-101 radiopharmaceutical programs for solid tumors. With no approved products or revenue in the latest opened filing, execution centers on regulatory work, clinical trials, radioisotope supply, and outside financing.
Develops clinical-stage medicines through licensing and internal work, with ALXN1840 as the dominant near-term program for Wilson disease. The MNPR-101 platform uses a humanized antibody targeting uPAR to carry imaging or therapeutic radioisotopes into solid-tumor programs.
Operations are based in Wilmette, Illinois, and the portfolio is tied mostly to U.S. regulatory and clinical execution. ALXN1840 came from an Alexion/AstraZeneca Rare Disease license, while MNPR-101 traces back to assets contributed at formation.
No approved products or revenue were reported in the latest opened annual filing. The business depends on FDA review of ALXN1840, early oncology trial execution, radioisotope supply, third-party manufacturing and trial providers, and continued financing.
Company facts
Unavailable right now.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $134.3M · Total debt $107.8K · Total assets $135.0M · Shareholders' equity $130.9M
- Revenue
- $0
- Operating income
- −$6.6M
- Net income
- −$5.3M
No dividends on record.
| Institutions | 92.91% | 6.24M shares | |
|---|---|---|---|
| 98 holders · as of Jun 30, 2026 | |||
| Insiders | 12.33% | 827.4K shares | |
| 10 holders · as of Aug 28, 2026 | |||
| Strategic holders | 31.02% | 2.08M shares | |
| 3 holders · as of Feb 6, 2026 | |||
| Adds to | 136.26% | ||
6.71M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
These groups come from separate filings that can overlap, so they add to 136.26%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Jupiter Topco LLCInstitution | 19.55% | 1.31M | as of Jun 30, 2026 |
Janus Henderson Group PLCStrategic | 19.18% | 1.29M | filed Nov 14, 2025 |
Ra Capital Management, L.P.Institution | 9.94% | 667,207 | as of Jun 30, 2026 |
Diane HendricksInsider10 percent owner | 8.46% | 567,580 | filed Dec 17, 2025 |
Alexion Pharmaceuticals, Inc.Strategic | 7.79% | 522,667 | filed Feb 6, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 26, 2026 | Kim R. Tsuchimoto | director | −4,090 | $111.39 |
| Aug 25, 2026 | Raymond Anderson | director | −3,788 | $111.65 |
| Aug 26, 2026 | Patrice Rioux | other: Acting Chief Medical Officer | −1 | $111.26 |
| Dec 26, 2025 | Quan Anh Vu | officer: Chief Financial Officer | +1,500 | $69.95 |
| Dec 18, 2025 | Arthur J. Klausner | director | −5,121 | $67.15 |
- Bausch Health
Markets established Wilson disease chelator therapies
- Novartis (ADR)
Leads approved radioligand oncology with Pluvicto and Lutathera
- Ultragenyx Pharmaceutical
Develops UX701 gene therapy for Wilson disease
- Eton Pharmaceuticals
Commercializes Galzin and develops ET-700 for Wilson disease
- Lantheus
Radiopharmaceutical diagnostics and therapy pipeline peer
- Telix Pharmaceuticals
Develops paired diagnostic and therapeutic radiopharmaceuticals
- Perspective Therapeutics
Clinical-stage alpha radiopharmaceutical oncology platform
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Monopar Therapeutics | $95.44 | −0.29% | $641.2M | — | — | — | — |
| Bausch Health | $5.70 | +0.98% | $2.11B | — | 1.3 | 0.2 | +11.2% |
| Novartis (ADR) | $141.06 | +0.06% | $267.96B | 21.3 | 15.0 | 4.8 | +0.9% |
| Ultragenyx Pharmaceutical | $15.28 | +4.30% | $1.44B | — | — | 2.0 | +28.5% |
| Eton Pharmaceuticals | $56.48 | +2.11% | $1.52B | 143.8 | 37.3 | 14.3 | +98.6% |
| Lantheus | $100.34 | +0.06% | $6.53B | 24.2 | 17.9 | 4.2 | +2.7% |
| Telix Pharmaceuticals | $11.93 | +5.48% | $3.83B | 114.7 | — | 4.1 | +22.2% |
| Perspective Therapeutics | $2.90 | −2.53% | $338.7M | — | — | 925.5 | −72.1% |
| Median | 69.5 | 16.4 | 4.2 | +11.2% |